ONO-2506PO + ONO-2506PO
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis (ALS)
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Trial Timeline
Nov 1, 2006 → Dec 1, 2008
NCT ID
NCT00403104About ONO-2506PO + ONO-2506PO
ONO-2506PO + ONO-2506PO is a phase 2 stage product being developed by Ono Pharmaceutical for Amyotrophic Lateral Sclerosis (ALS). The current trial status is completed. This product is registered under clinical trial identifier NCT00403104. Target conditions include Amyotrophic Lateral Sclerosis (ALS).
What happened to similar drugs?
2 of 18 similar drugs in Amyotrophic Lateral Sclerosis (ALS) were approved
Approved (2) Terminated (4) Active (12)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00403104 | Phase 2 | Completed |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis (ALS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 17 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 35 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 18 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 38 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 38 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 40 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 35 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 36 |
| TCH346 | Novartis | Phase 2 | 35 |
| VHB937 | Novartis | Phase 2 | 39 |
| TCH346 | Novartis | Phase 2 | 35 |
| TCH346 | Novartis | Phase 2 | 35 |
| BLZ945 | Novartis | Phase 2 | 27 |
| TRO19622 | Roche | Phase 2/3 | 38 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 40 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 28 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 35 |
| DNL747 + Placebo | Sanofi | Phase 1 | 21 |